IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 3760 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  Search
 
  Next article
  Previous article 
  Table of Contents
  
Resource Links
   Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
   Article in PDF (74 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)

 
In This Article
   Acknowledgements
   References

 Article Access Statistics
    Viewed5120    
    Printed182    
    Emailed3    
    PDF Downloaded179    
    Comments [Add]    
    Cited by others 2    

Recommend this journal

 
RESEARCH LETTER
Year : 2004  |  Volume : 36  |  Issue : 6  |  Page : 381-382
 

Antihypertensive effect of newly synthesized acyl amino substituted propanolamine derivatives, DPJ 890 and DPJ 955 in rats


Department of Pharmacology, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Erandwane, Pune - 411 038, India

Correspondence Address:
Department of Pharmacology, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Erandwane, Pune - 411 038, India
[email protected]



How to cite this article:
Nandakumar K, Singh R, Bansal S K, Bodhankar S L, Jindal D P, Coumar M S, Bhardwaj S H. Antihypertensive effect of newly synthesized acyl amino substituted propanolamine derivatives, DPJ 890 and DPJ 955 in rats. Indian J Pharmacol 2004;36:381-2


How to cite this URL:
Nandakumar K, Singh R, Bansal S K, Bodhankar S L, Jindal D P, Coumar M S, Bhardwaj S H. Antihypertensive effect of newly synthesized acyl amino substituted propanolamine derivatives, DPJ 890 and DPJ 955 in rats. Indian J Pharmacol [serial online] 2004 [cited 2021 Oct 28];36:381-2. Available from: https://www.ijp-online.com/text.asp?2004/36/6/381/13512


Sir,

Hypertension described as a 'silent killer' increases the incidence of cardiovascular diseases. blockers have been widely used since more than four decades for the treatment of hypertension. However these drugs are contraindicated in asthmatics and diabetics.[1] In order to improve the therapeutic variety, Late D. P. Jindal (Panjab University) had synthesized new compounds for blocking activity. The synthesis and adrenoreceptor ( 1 and 2) binding affinities of these compounds were reported earlier.[2] Previous work indicated that DPJ 890 and DPJ 955 possessed greater 1 adrenoreceptor selectivity than standard blocking drugs like atenolol and propranolol among various compounds synthesized from the series. As a collaborative research work we received compound DPJ 890 and DPJ 955, which are chemically N[4 - (3 - tert - butylamino - 2 - hydroxy - propoxy) - phenyl] - 3,4 - dimethoxy benzamide oxalate and N[5 - (3 - tert - butylamino - 2 - hydroxy - propoxy) - naphthalene-1-yl] - acetamide oxalate respectively for evaluating the antihypertensive potential.

Female Wistar rats (175-200 g) purchased from the National Toxicology Centre, Pune, India, were housed in a clean environment, at a temperature of 251o C and a relative humidity of 45 to 55%, under 12/12 h light/dark cycle. The animals had free access to food pellets (Chakan Oil Mills, Pune, India). The research protocol was approved by the Institutional Animal Ethics Committee (IAEC) of the Poona College of Pharmacy, Pune, India.

Two-kidney 1 clip model of kidney ligation was used to produce hypertension in rats. Group I animals had not undergone renal ligation. Rats were anesthetized with urethane (1.25 mg/kg, i.p.) and the left renal artery (LRA) was ligated[3] except in Group I rats. After renal ligation the animals were housed and provided with 1% sodium chloride solution instead of water. After 6 weeks of LRA ligation the animals were divided into 9 groups consisting of 6 animals in each group. Group II received vehicle [saline (0.9% sodium chloride in water), 1 ml/kg, i.p.], which served as LRA ligated control. Groups III, IV, V, VI, VII and VIII received a dose of DPJ 955 (3, 10 or 30 mg/kg) or DPJ 890 (1, 3 or 10 mg/kg) intraperitoneally, respectively. Groups IX and X received standard drug propranolol (30 mg/kg, i.p.) and atenolol (10 mg/kg, i.p.) respectively. Saline or drug treatment was initiated after 6 weeks of LRA ligation and treatment was continued for 7 days. The mean arterial pressure (MAP) was recorded by directly cannulating the carotid artery using four-channel physiological data acquisition system (MP 30, BIOPAC Systems, Inc., Santa Barbara, CA). MAP was recorded at the end of the 7th week, 1 h after the administration of the last dose of saline or test drugs. The heart rate was computed from the ECG recording.

The statistical significance of the difference between means was determined using one-way analysis of variance followed by Tukey test. P<0.05 was considered significant. LRA ligation after 7 weeks had significantly (P<0.01) increased the MAP compared to non-ligated rats. However, the heart rate was not significantly changed as compared to non-ligated rats. Treatment with DPJ 890 (1, 3 and 10 mg/kg, i.p.) and DPJ 955 (3, 10 and 30 mg/kg, i.p.) produced a significant, dose dependent decrease in the MAP and heart rate of LRA ligated rats. Significant reduction in MAP and heart rate was observed in hypertensive rats treated with propranolol (30 mg/kg), atenolol (10 mg/kg), DPJ 890 (3 and 10 mg/kg) and DPJ 955 (10 and 30 mg/kg). The fall in the the MAP produced by DPJ 890 (10 mg/kg) was greater compared to atenolol and propranolol while the effect of DPJ 955 was less than that of atenolol but greater than that of propranolol [Table - 1].

The observed change in the MAP and heart rate in LRA ligated rats with DPJ 890 may be due to its stronger receptor (1) binding property compared to atenolol.


  Acknowledgements Top


The authors would like to thank Dr. R. Balaraman, Professor, Department of Pharmacology, G. S. Patel Postgraduate Center for Pharmaceutical Education and Research, Vadodara, India for his valuable suggestions. The authors are thankful to The Principal, Dr. S. S. Kadam and Vice Principal, Dr. K. R. Mahadik of the Poona College of Pharmacy, for their encouragement and support. 

  References Top

1.Hoffman BB. Catecholamines, Sympathomimetic drugs and adrenergic receptor antagonists In: Hardman JG, Limbird LE, editors. Goodman and Gilman's. The Pharmacological Basis of Therapeutics. 10th Ed. New York: McGraw Hill Companies; 2001. p. 215-67.  Back to cited text no. 1    
2.Jindal DP, Coumar MS, Bruni G, Massarelli P. Synthesis and beta 1-, beta 2-adrenergic receptor binding studies of 4-acylamino-substituted phenoxypropanolamine and 5-acylamino-substituted naphthyloxypro-panolamine derivatives. Arzneimittelforschung 2002;52:654-63.  Back to cited text no. 2  [PUBMED]  
3.Cangiano JL, Sargent CR, Malnado MM. Effects of antihypertensive treatment on systolic blood pressure and renin in experimental hypertension in rats. J Pharmacol Expt Ther 1979;208:310-3.  Back to cited text no. 3    
Top
Print this article  Email this article

    

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow